KeshuZhou

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients suffering from hematological, cardiovascular, and musculoskeletal disorders. The company leverages its deep understanding of the transforming growth factor-beta (TGF-beta) family of proteins to design "ligand traps" that modulate signaling pathways involved in tissue growth and repair. Its lead clinical candidates include elritercept (KER-050) for the treatment of low blood cell counts in myelodysplastic syndromes and myelofibrosis, and cibotercept (KER-012) for pulmonary arterial hypertension and heart failure. By targeting specific ligands within the TGF-beta superfamily, Keros aims to provide differentiated therapies that address significant unmet medical needs in chronic diseases.